Estrogen Receptor Modulators Market size was valued at USD 16.3 billion in 2024 and is anticipated to surpass USD 36.3 billion by 2037, registering a CAGR of 6.9% during the forecast timeline i.e. 2025-2037. In 2025, the industry size of estrogen receptor modulators is assessed at USD 17.4 billion.
The growth of estrogen receptor modulators market is influenced by their therapeutic significance and versatility. The growing incidence of estrogen-dependent conditions, especially breast cancer, necessitates the development of targeted therapies that can effectively modulate estrogen activity. Moreover, such instances are most commonly found in women. For instance, according to reports published by WHO in the year 2022, 670,000 women lost their lives to breast cancer and 2.3 million women received a diagnosis. Furthermore, in December 2024, it was unveiled that approximately 310,720 women received a diagnosis of invasive breast cancer, with women under 50 years of age accounting for 16% of these cases.
In addition, massive strides in pharmacological research in the estrogen receptor modulators market have discovered new ERMs such as selective estrogen receptor modulators (SERMs), that show improved selectivity and efficacy than their conventional analogs. Furthermore, they have been crucial in this regard because they offer a dual mechanism where they can act as estrogen agonists in some tissues but antagonists in others, thus reducing the side effects related to hormone action. For instance, in December 2023, the new approaches to combat ESR1-mutant breast cancer, such as innovative selective estrogen receptor degraders (SERDs) and SERMs were reviewed at a State-of-the-Art Session at the 2023 San Antonio Breast Cancer Symposium. At present, elacestrant is the sole approved oral drug for ER+, HER2- metastatic ESR1-mutated breast cancer.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.9% |
|
Base Year Market Size (2024) |
USD 16.3 billion |
|
Forecast Year Market Size (2037) |
USD 36.3 billion |
|
Regional Scope |
|
Type (Breast Cancer Treatment, Vaginitis, Osteoporosis, Others)
Breast cancer treatment segment is expected to account for more than 51.2% estrogen receptor modulators market share by the end of 2037. It is primarily due to the high prevalence of hormone receptor-positive breast cancer, which accounts for a significant proportion of all such cases. For instance, in February 2023, according to the WHO report, high-income nations have 5-year survival rates of over 90%, while South Africa and India have rates of 40% and 66%, respectively. Moreover, access to high-quality, resource-appropriate services must be systematically improved in order to close the disparities in breast cancer outcomes.
Established in 2021, the World Health Organization's Global Breast Cancer Initiative (GBCI) unites stakeholders from various sectors and around the world with the common objective of reducing breast cancer by 2.5% annually, which would save 2.5 million lives over a 20-year period. Because this focus on therapeutics remarkable benefits of modulation for the inhibition of tumor growth by estrogen receptor have been evident. In addition, as indicated for these agents across all clinical disciplines and improved outcome of the treatment in the clinics, the scope, thus, translates to an influential representation in the context of market share as well.
Application (Breast Cancer, Postmenopausal Osteoporosis, Others)
The breast cancer segment is anticipated to dominate the estrogen receptor modulators market by 2037. Since these agents have proven to show spectacular efficacy for treating hormone receptor-positive breast cancer. The focus on well-researched and developed treatments will play crucial role in improving patient survival and the quality of their life post such diagnosis, especially against this dominant cause of cancer. For instance, in October 2024, it was published in the National Institutes of Health that clinical trials of inavolisib, palbociclib, and fulvestrant together produced encouraging results. This established a new standard of care for patients with advanced breast cancer that is PIK3CA-mutant, hormone receptor-positive, and HER2-negative.
Moreover, estrogen receptor modulators selectively target estrogen effects on tumor growth and therefore provide a backbone for adjuvant and metastatic treatment settings. For instance, in June 2021, Sanofi is collaborating with the European Organization for Research and Treatment of Cancer, the Breast International Group, and Alliance Foundation Trials, that provide clinical research on breast cancer that is revolutionizing practice. Working together, the Phase 3 AMEERA-6 study assessed the safety and effectiveness of Sanofi's investigational amcenestrant in estrogen receptor-positive (ER+) patients. This study is anticipated to be the first pivotal trial of an oral selective estrogen receptor degrader (SERD) in the adjuvant setting.
Our in-depth analysis of the global estrogen receptor modulators market includes the following segments:
|
Type |
|
|
Application |
|
North America Market Statistics
North America estrogen receptor modulators market is projected to dominate revenue share of over 43.2% by 2037. Furthermore, the value of ERMs has gained increasing recognition through regulatory agencies with accelerated approval processes for innovative formulations addressing unmet medical needs. This has been a strong impetus for pharmaceutical companies to invest considerably in research and development efforts toward broadening the therapeutic potential of ERMs in the region.
The U.S. is experiencing an exceptional growth in the estrogen receptor modulators market attributable to the rising prevalence and awareness of early detection to ensure increased recovery rate. For instance, in August 2024, it was revealed by the National Breast Cancer Foundation that about 1 in 8 women, or 13% of all women in the U.S., will get breast cancer at some point in their lives. The 5-year relative survival rate is 99% if the disease is detected in its earliest locations. Moreover, over 4 million people in the US have survived breast cancer as of right now.
In Canada, the estrogen receptor modulators market is experiencing a significant growth owing to the supportive regulatory framework that foster a conducive ecosystem for growth. For instance, in July 2023, Atossa Therapeutics, Inc. announced that Health Canada has granted a no objection letter in response to the company's clinical trial application for its Phase 2 EVANGELINE study. In addition, Atossa's patented SERM, (Z)-endoxifen, and exemestane plus goserelin are being used as a neoadjuvant treatment for premenopausal women. In regard to grade 1 or 2 estrogen receptor positive (ER+) / human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
Asia Pacific Market Analysis
The estrogen receptor modulators market in Asia Pacific is gaining traction and is expected to witness lucrative growth during the forecast timeline i.e. 2025-2037. Ongoing clinical trials of combinations of therapies which include ERMs, are exhibiting synergies that will hope to improve a treatment outcome among a range of patient populations in the region. As more awareness about personalized medicine approaches for the optimization of hormonal therapies the market for ERMs is very well poised to continue growth with both clinical efficacy and safety profiles.
In India the estrogen receptor modulators market is witnessing a substantial surge attributable to the heavy investments in R&D activities to shape the state-of-the-art healthcare facilities. For instance, in October 2024, the acquisition of USD 1 million in seed funding by cancer care start-up Oncare was the major step forward for India's healthcare industry. The company strategizes to collaborate with mid-sized hospitals, usually those with 50–100 beds in contrast to the unaffordable treatments offered in corporate hospitals and approach to cut the cost of cancer treatment by up to 40%.
In China the estrogen receptor modulators market is witnessing a strong influence due to the clinical trials and successions by companies to reshape the applications of treatment for effectiveness. For instance, in December 2024, Shanghai Henlius Biotech, Inc. reported that the first patient in China received a dose of HLX78 (oral lasofoxifene) in combination with abemaciclib (a CDK4/6 inhibitor) in the international multi-center Phase 3 clinical trial (ELAINE-3, NCT05696626) for patients with locally advanced or metastatic ER+/HER2- breast cancer.
To create state-of-the-art diagnostic solutions, established players in the estrogen receptor modulators market, primarily concentrate on innovation and technological advancements. They also collaborate with up-and-coming players to take advantage of their technology. For instance, in January 2024, Insilico Medicine and Menarini Group, via its Stemline subsidiary, inked an exclusive licensing agreement. With the help of Insilico's AI, Stemline acquires the worldwide rights to create and market a novel small-molecule KAT6A inhibitor for hormone-sensitive and other cancers.
Here's the list of some key players:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?